Territorial Availability: Available through Bertin Technologies only in France
Technical Warning: Bertin Technologies restricts the sale of this product to licensed controlled substance laboratories and qualified academic research institutions. Please contact us for further details.
Special Advice: Dangerous Good in said quantity, not available for sale.
- Synonyms
- 2,3-dimethoxy-strychnidin-10-one
- Correlated keywords
- 54193-32-7 70206-61-0 101324-32-7 193198-03-7 462651-43-0 1087723-67-8 1195340-33-0 1195623-19-8 Strychnine antiinflammatory anti-cancer oxidant PGE E 2 DM BA G PX M 1 Dimethoxystrychnidin
- Product Overview:
Brucine is an alkaloid that has been found in the seeds of the S. nux-vomica tree and has diverse biological activities, including anti-inflammatory, anticancer, and antioxidant properties.{47322} It inhibits prostaglandin E2 (PGE2; Item No. 14010) production induced by LPS in vitro.{47323} Topical administration of brucine decreases synoviocyte proliferation and reduces paw and joint swelling in a rat model of adjuvant-induced arthritis and decreases swelling in a mouse model of xylene-induced ear edema. Brucine (4 and 8 mg/kg per day) reduces tumor incidence, number, and volume in a rat model of mammary gland tumorigenesis induced by 7,12-dimethylbenz(a)anthracene (DMBA).{47322} It prevents decreases in superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPX) activity and increases the level of glutathione (GSH) in mammary tissues, as well as reduces markers of lipid peroxidation in plasma and mammary tissue. Brucine also allosterically enhances the effect of low, but not high, concentrations of acetylcholine at M1 muscarinic acetylcholine receptors.{47324}
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.